Retraction notice to “Predictive and prognostic value of ER-α36 expression in breast cancer patients treated with chemotherapy” [Steroids 84 (2014) 11–16](S0039128X14000488)(10.1016/j.steroids.2014.03.003);RETRACTED: Predictive and prognostic value of ER-?36 expression in breast cancer patients treated with chemotherapy

Steroids

Volumn 84, Issue , 2014, Pages 11-16

  Yu, Lanfang ^a   Ke, Wei ^a   Wang, Yanli ^a   Ding, Wei ^a   Wang, Bo ^a   Huang, Sui ^a   Chen, Jing ^a   Wang, Xiaoting ^a   Wang, Zhaoyi ^b   Shen, Peng ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Breast cancer; Chemotherapy; ER 36; Prognosis

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR ALPHA36; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; UNCLASSIFIED DRUG; ISOPROTEIN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER PROGNOSIS; CANCER REGRESSION; CANCER SURGERY; CANCER SURVIVAL; DISEASE FREE SURVIVAL; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PREDICTIVE VALUE; PROTEIN EXPRESSION; TREATMENT OUTCOME; TREATMENT RESPONSE; TRIPLE NEGATIVE BREAST CANCER; TUMOR VOLUME; YOUNG ADULT; BREAST NEOPLASMS; FEMALE; METABOLISM; PATHOLOGY; PROGNOSIS;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; ESTROGEN RECEPTOR ALPHA; FEMALE; HUMANS; MIDDLE AGED; PROGNOSIS; PROTEIN ISOFORMS;

EID: 84897450130     PISSN: 0039128X     EISSN: 18785867     Source Type: Journal    
DOI: 10.1016/j.steroids.2016.02.001     Document Type: Erratum

References (30)

1. R. Siegel, D. Naishadham, and A. Jemal Cancer statistics, 2012 CA Cancer J Clin 62 2012 10 29
2. C. Bernard-Marty, M. Mano, M. Paesmans, C. Accettura, R. Munoz-Bermeo, and T. Richard et al. Second malignancies following adjuvant chemotherapy: 6-year results from a Belgian randomized study comparing cyclophosphamide, methotrexate and 5-fluorouracil (CMF) with an anthracycline-based regimen in adjuvant treatment of node-positive breast cancer patients Ann Oncol 14 2003 693 698 (Pubitemid 36621767)
3. M. Ayers, W. Symmans, J. Stec, A. Damokosh, E. Clark, and K. Hess et al. Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer J Clin Oncol 22 2004 2284 2293 (Pubitemid 41115384)
4. I.C. Smith, S.D. Heys, A.W. Hutcheon, I.D. Miller, S. Payne, and F.J. Gilbert et al. Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel J Clin Oncol 20 2002 1456 1466 (Pubitemid 34260523)
5. J.A. Sparano, M. Wang, S. Martino, V. Jones, E.A. Perez, and T. Saphner et al. Weekly paclitaxel in the adjuvant treatment of breast cancer N Engl J Med 358 2008 1663 1671 (Pubitemid 351549913)
6. S.H. Giordano, Y.-L. Lin, Y.F. Kuo, G.N. Hortobagyi, and J.S. Goodwin Decline in the use of anthracyclines for breast cancer J Clin Oncol 30 2012 2232 2239
7. C.S. Ross-Innes, R. Stark, K.A. Holmes, D. Schmidt, C. Spyrou, and R. Russell et al. Cooperative interaction between retinoic acid receptor-α and estrogen receptor in breast cancer Genes Dev 24 2010 171 182
8. G. Arpino, L. Wiechmann, C.K. Osborne, and R. Schiff Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance Endocr Rev 29 2008 217 233 (Pubitemid 351519691)
9. Z. Wang, X. Zhang, P. Shen, B.W. Loggie, Y. Chang, and T.F. Deuel Identification, cloning, and expression of human estrogen receptor-α36, a novel variant of human estrogen receptor-α66 Biochem Biophys Res Commun 336 2005 1023 1027 (Pubitemid 41383424)
10. Z. Wang, X. Zhang, P. Shen, B.W. Loggie, Y. Chang, and T.F. Deuel A variant of estrogen receptor-α, hER-α36: transduction of estrogen-and antiestrogen-dependent membrane-initiated mitogenic signaling Proc Natl Acad Sci 103 2006 9063 9068 (Pubitemid 43902533)
11. S.-L. Lin, L.-Y. Yan, X.-T. Zhang, J. Yuan, M. Li, and J. Qiao ER-α36, a variant of ER-α, promotes tamoxifen agonist action in endometrial cancer cells via the MAPK/ERK and PI3K/Akt pathways PLoS ONE 5 2010 e9013
12. X. Zhang, L. Ding, L. Kang, and Z.-Y. Wang Estrogen receptor-alpha 36 mediates mitogenic antiestrogen signaling in ER-negative breast cancer cells PLoS ONE 7 2012 e30174
13. J. Zhang, G. Li, Z. Li, X. Yu, Y. Zheng, and K. Jin et al. Estrogen-independent effects of ER-α36 in ER-negative breast cancer Steroids 77 2012 666 673
14. E. Lips, L. Mulder, J. De Ronde, I. Mandjes, A. Vincent, and M.V. Peeters et al. Neoadjuvant chemotherapy in ER+ HER2- breast cancer: response prediction based on immunohistochemical and molecular characteristics Breast Cancer Res Treat 131 2012 827 836
15. S.E. Singletary, C. Allred, P. Ashley, L.W. Bassett, D. Berry, and K.I. Bland et al. Staging system for breast cancer: revisions for the 6th edition of the AJCC Cancer Staging Manual Surg Clin North Am 83 2003 803 819 (Pubitemid 36841911)
16. L. Shi, B. Dong, Z. Li, Y. Lu, T. Ouyang, and J. Li et al. Expression of ER-α36, a novel variant of estrogen receptor α, and resistance to tamoxifen treatment in breast cancer J Clin Oncol 27 2009 3423 3429
17. H.M. Kuerer, A.A. Sahin, K.K. Hunt, L.A. Newman, T.M. Breslin, and F.C. Ames et al. Incidence and impact of documented eradication of breast cancer axillary lymph node metastases before surgery in patients treated with neoadjuvant chemotherapy Ann Surg 230 1999 72
18. R. Rouzier, L. Pusztai, S. Delaloge, A.M. Gonzalez-Angulo, F. Andre, and K.R. Hess et al. Nomograms to predict pathologic complete response and metastasis-free survival after preoperative chemotherapy for breast cancer J Clin Oncol 23 2005 8331 8339
19. Y. Zheng, J. Zhang, Z.-Z. Xu, J.-M. Sheng, X.-C. Zhang, and H.-H. Wang et al. Quantitative profiles of the mRNAs of ER-α and its novel variant ER-α36 in breast cancers and matched normal tissues J Zhejiang Univ Sci B 11 2010 144 150
20. J. Kim, J. Lee, E. Chang, K. Suh, C. Lee, J. Jee, and H. Shin Prognostic factors in patients with stage II/III breast cancer treated with adjuvant extension of neoadjuvant chemotherapy: a retrospective cohort study with ten-years of follow-up data J Breast Cancer 14 2011 39 45
21. P.M. Spanheimer, J.C. Carr, A. Thomas, S.L. Sugg, C.E. Scott-Conner, and J. Liao et al. The response to neoadjuvant chemotherapy predicts clinical outcome and increases breast conservation in advanced breast cancer Am J Surg 2013
22. K.I. Pritchard, L.E. Shepherd, F.P. O'malley, I.L. Andrulis, D. Tu, and V.H. Bramwell et al. HER2 and responsiveness of breast cancer to adjuvant chemotherapy N Engl J Med 354 2006 2103 2111 (Pubitemid 43736610)
23. M.E.H. Hammond, D.F. Hayes, M. Dowsett, D.C. Allred, K.L. Hagerty, and S. Badve et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version) Arch Pathol Lab Med 134 2010 e48 e72
24. R. Nishimura, T. Osako, Y. Okumura, M. Hayashi, and N. Arima Clinical significance of Ki-67 in neoadjuvant chemotherapy for primary breast cancer as a predictor for chemosensitivity and for prognosis Breast Cancer 17 2010 269 275
25. P. Eroles, A. Bosch, B. Bermejo, and A. Lluch Mechanisms of resistance to hormonal treatment in breast cancer Clin Transl Oncol 12 2010 246 252
26. C.S. Fisher, C.X. Ma, W.E. Gillanders, T.J. Eberlein, and J.A. Margenthaler Neoadjuvant chemotherapy is associated with improved survival compared with adjuvant chemotherapy in patients with triple-negative breast cancer only after complete pathologic response Ann Surg Oncol 19 2012 253 258
27. L.A. Carey, C.M. Perou, C.A. Livasy, L.G. Dressler, D. Cowan, and K. Conway et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study JAMA 295 2006 2492 2502 (Pubitemid 43854964)
28. R. Dent, W.M. Hanna, M. Trudeau, E. Rawlinson, P. Sun, and S.A. Narod Pattern of metastatic spread in triple-negative breast cancer Breast Cancer Res Treat 115 2009 423 428
29. J.S. Parker, M. Mullins, M.C. Cheang, S. Leung, D. Voduc, and T. Vickery et al. Supervised risk predictor of breast cancer based on intrinsic subtypes J Clin Oncol 27 2009 1160 1167
30. C. Liedtke, C. Mazouni, K.R. Hess, F. André, A. Tordai, and J.A. Mejia et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer J Clin Oncol 26 2008 1275 1281